New York City-based Memorial Sloan Kettering Cancer Center is collaborating with oncology-focused startup Triomics to implement an AI-powered platform that supports clinical trial matching and screening across its research portfolio.
The technology, developed by Triomics, automatically analyzes patient records to identify eligible clinical trials and provides source citations to streamline enrollment decisions, according to a Nov. 4 news release. The rollout will occur in two phases and is being led by the MSK Clinical Research Innovation Consortium and MSK Innovation Hub teams.
Triomics joined MSK’s Innovation Hub after participating in the 2024 iHub Challenge program. The integration aims to reduce the time required to prescreen patient records — a manual process that can take up to 45 minutes per patient — and help clinical teams avoid missed trial opportunities.
